Total Payments
$50,892
2024 Payments
$710.15
Companies
54
Transactions
399
Medicare Patients
1,921
Medicare Billing
$379,697
Payment Breakdown by Category
Consulting$44,208 (86.9%)
Food & Beverage$6,084 (12.0%)
Education$348.09 (0.7%)
Travel$252.42 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $44,208 | 7 | 86.9% |
| Food and Beverage | $6,084 | 371 | 12.0% |
| Education | $348.09 | 20 | 0.7% |
| Travel and Lodging | $252.42 | 1 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Daiichi Sankyo Inc. | $42,169 | 109 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $3,737 | 18 | $0 (2024) |
| Novartis Pharmaceuticals Corporation | $416.42 | 29 | $0 (2024) |
| Lilly USA, LLC | $414.99 | 29 | $0 (2020) |
| PFIZER INC. | $344.08 | 28 | $0 (2024) |
| Genentech USA, Inc. | $331.81 | 26 | $0 (2020) |
| Amgen Inc. | $322.58 | 18 | $0 (2023) |
| Takeda Pharmaceuticals U.S.A., Inc. | $305.00 | 9 | $0 (2020) |
| PUMA BIOTECHNOLOGY, INC. | $297.97 | 5 | $0 (2021) |
| Clovis Oncology, Inc. | $258.19 | 12 | $0 (2019) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $710.15 | 38 | Daiichi Sankyo Inc. ($221.50) |
| 2023 | $609.83 | 52 | Daiichi Sankyo Inc. ($369.91) |
| 2022 | $358.63 | 39 | Daiichi Sankyo Inc. ($233.60) |
| 2021 | $1,212 | 5 | Daiichi Sankyo Inc. ($1,028) |
| 2020 | $43,981 | 28 | Daiichi Sankyo Inc. ($40,161) |
| 2019 | $1,219 | 92 | Genentech USA, Inc. ($160.67) |
| 2018 | $2,235 | 115 | Clovis Oncology, Inc. ($237.20) |
| 2017 | $566.08 | 30 | Millennium Pharmaceuticals, Inc. ($91.10) |
All Payment Transactions
399 individual payment records from CMS Open Payments — Page 2 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 04/12/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $22.06 | General |
| Category: Iron Deficiency Anemia | ||||||
| 04/12/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $3.63 | General |
| Category: Iron Deficiency Anemia | ||||||
| 03/28/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $22.87 | General |
| 02/29/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $29.56 | General |
| Category: Iron Deficiency Anemia | ||||||
| 02/29/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $25.18 | General |
| Category: Hematology | ||||||
| 02/20/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $23.98 | General |
| Category: Oncology | ||||||
| 02/14/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $17.42 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 02/08/2024 | Daiichi Sankyo Inc. | Vanflyta (Drug) | Food and Beverage | In-kind items and services | $6.70 | General |
| Category: ONCOLOGY | ||||||
| 02/06/2024 | ABBVIE INC. | EPKINLY (Drug), IMBRUVICA | Food and Beverage | In-kind items and services | $23.79 | General |
| Category: ONCOLOGY | ||||||
| 02/01/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $22.53 | General |
| Category: Oncology | ||||||
| 01/30/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $8.78 | General |
| Category: ONCOLOGY | ||||||
| 01/18/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $6.97 | General |
| Category: Iron Deficiency Anemia | ||||||
| 01/11/2024 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $28.34 | General |
| Category: Iron Deficiency Anemia | ||||||
| 12/20/2023 | Secura Bio, Inc. | COPIKTRA (Drug) | Food and Beverage | In-kind items and services | $18.14 | General |
| Category: ORAL ONCOLOGIC | ||||||
| 10/04/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $27.26 | General |
| Category: ONCOLOGY | ||||||
| 09/26/2023 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $14.95 | General |
| 09/21/2023 | Bayer Healthcare Pharmaceuticals Inc. | Stivarga (Drug), Vitrakvi | Food and Beverage | In-kind items and services | $27.51 | General |
| Category: Oncology | ||||||
| 09/20/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $7.15 | General |
| Category: ONCOLOGY | ||||||
| 09/19/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $18.57 | General |
| Category: ONCOLOGY | ||||||
| 09/19/2023 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $16.50 | General |
| Category: Oncology | ||||||
| 09/12/2023 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $23.04 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 08/29/2023 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $27.58 | General |
| Category: ONCOLOGY | ||||||
| 08/22/2023 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $23.40 | General |
| Category: ONCOLOGY | ||||||
| 07/18/2023 | Kite Pharma, Inc. | Yescarta (Drug) | Food and Beverage | In-kind items and services | $30.01 | General |
| Category: CELLT | ||||||
| 06/28/2023 | Daiichi Sankyo Inc. | INJECTAFER (Drug) | Food and Beverage | In-kind items and services | $7.86 | General |
| Category: Iron Deficiency Anemia | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 21 | 478 | 3,017 | $229,184 | $59,940 |
| 2022 | 20 | 546 | 1,836 | $312,061 | $98,258 |
| 2021 | 17 | 519 | 2,358 | $283,082 | $116,697 |
| 2020 | 15 | 378 | 16,334 | $269,933 | $104,801 |
Total Patients
1,921
Total Services
23,545
Medicare Billing
$379,697
Procedure Codes
73
All Medicare Procedures & Services
73 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 39 | 101 | $35,350 | $12,462 | 35.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 74 | 136 | $37,550 | $12,021 | 32.0% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 22 | 94 | $38,728 | $9,182 | 23.7% |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | Office | 2023 | 26 | 330 | $9,900 | $3,881 | 39.2% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 17 | 39 | $9,750 | $3,562 | 36.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 37 | 55 | $9,625 | $3,365 | 35.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 15 | 15 | $7,500 | $2,353 | 31.4% |
| 99426 | Principal care management services for a single high-risk disease, first 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 17 | 48 | $7,680 | $2,240 | 29.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 13 | 13 | $6,500 | $1,729 | 26.6% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 11 | 71 | $7,100 | $1,536 | 21.6% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 42 | 142 | $7,100 | $1,459 | 20.6% |
| 96415 | Administration of chemotherapy into vein, each additional hour | Office | 2023 | 11 | 59 | $5,487 | $1,271 | 23.2% |
| 96375 | Injection of additional new drug or substance into vein | Office | 2023 | 15 | 97 | $6,790 | $1,144 | 16.8% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 38 | 147 | $4,704 | $1,111 | 23.6% |
| 99427 | Principal care management services for a single high-risk disease, each additional 30 minutes of clinical staff time directed by health care professional, per calendar month | Office | 2023 | 14 | 25 | $3,000 | $900.21 | 30.0% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 12 | 16 | $3,040 | $647.80 | 21.3% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 15 | 37 | $2,220 | $361.43 | 16.3% |
| J2469 | Injection, palonosetron hcl, 25 mcg | Office | 2023 | 11 | 400 | $20,800 | $337.21 | 1.6% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 22 | 27 | $270.00 | $226.80 | 84.0% |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | Office | 2023 | 13 | 1,112 | $5,560 | $105.52 | 1.9% |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | Office | 2023 | 14 | 53 | $530.00 | $45.04 | 8.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 111 | 239 | $65,725 | $22,721 | 34.6% |
| G9678 | Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | Office | 2022 | 37 | 120 | $19,200 | $19,162 | 99.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 57 | 110 | $38,500 | $15,277 | 39.7% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 26 | 131 | $53,972 | $14,176 | 26.3% |
About Dr. Deepna Jaiswal, D.O
Dr. Deepna Jaiswal, D.O is a Hematology & Oncology healthcare provider based in Plano, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/25/2011. The National Provider Identifier (NPI) number assigned to this provider is 1447541594.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Deepna Jaiswal, D.O has received a total of $50,892 in payments from pharmaceutical and medical device companies, with $710.15 received in 2024. These payments were reported across 399 transactions from 54 companies. The most common payment nature is "Consulting Fee" ($44,208).
As a Medicare-enrolled provider, Jaiswal has provided services to 1,921 Medicare beneficiaries, totaling 23,545 services with total Medicare billing of $379,697. Data is available for 4 years (2020–2023), covering 73 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Plano, TX
- Active Since 04/25/2011
- Last Updated 02/06/2025
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1447541594
Products in Payments
- Enhertu (Drug) $41,392
- INJECTAFER (Drug) $619.95
- Rubraca (Drug) $258.19
- ZEJULA (Drug) $194.92
- XTANDI (Drug) $184.89
- VERZENIO (Drug) $182.18
- NINLARO (Drug) $172.84
- Nerlynx (Drug) $162.04
- VELCADE (Drug) $156.44
- NERLYNX (Drug) $135.93
- AFINITOR (Drug) $135.54
- LYNPARZA (Drug) $134.91
- ENHERTU (Drug) $127.82
- OPDIVO (Biological) $117.97
- Nplate (Biological) $117.46
- BOSULIF (Drug) $109.68
- KEYTRUDA (Biological) $107.66
- JEVTANA (Drug) $107.38
- Neulasta (Biological) $101.49
- IBRANCE (Drug) $90.58
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Plano
Ruben Saez, Md, MD
Hematology & Oncology — Payments: $117,913
Hematology & Oncology $117,913
Dr. Thuy Le, M.d, M.D
Hematology & Oncology — Payments: $22,323
Hematology & Oncology $22,323
Andrew Kovoor, Md, MD
Hematology & Oncology — Payments: $13,233
Hematology & Oncology $13,233
Virginia Kinsella, Md, MD
Hematology & Oncology — Payments: $13,129
Hematology & Oncology $13,129
Dr. Wendy Mahone-Johnson, Md, MD
Hematology & Oncology — Payments: $8,818
Hematology & Oncology $8,818
Dr. Nandita Rao, Md, MD
Hematology & Oncology — Payments: $4,337
Hematology & Oncology $4,337